Skip to main content
. 2019 Jun 7;19:49. doi: 10.1186/s12894-019-0481-5

Fig. 2.

Fig. 2

Forest plot reflects the association between TKIs-induced hypertension and oncologic outcomes (overall survival) in different TKIs subgroups (1: axitinib; 2: sorafenib; 3: sunitinib; 4: pazopanib)